Institutional investors hold a majority ownership of PRGO through the 81.16% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Pharmaceuticals: Other industry. Last, during the quarter ended December 2017, these large investors purchased a net $4.1 million shares.
Mutual fund holders | 42.64% |
Other institutional | 38.52% |
Individual stakeholders | 11.42% |